A single drug can have many uses. This is certainly the case for Avastin ( bevacizumab ), which is widely used to treat a number of different kinds of cancer. The drug may protect against the spread of yet another.

One of the most exciting frontiers in oncology is discovering molecular behavior that responds to existing drug therapies. Just such a discovery has been made regarding a deadly form of brain cancer.

Medicare has announced it will pay for Provenge ( sipuleucel-T ) to treat metastatic prostate cancer. This drug extends the life of patients by about four months.

In an unprecedented appeals hearing, the US Food and Drug Administration (FDA) has not changed its mind.  An FDA panel voted that the drug Avastin no longer be approved for treating late-stage breast cancers.

Even though a U.S. Food and Drug Administration (FDA) panel has voted to no longer approve Avastin ( bevacizumab ) for treating late-stage breast cancers, Medicare has indicated it will continue to pay for the drug.

In a first ever hearing, the U.S. Food and Drug Administration is considering reversing itself on a ruling to withdraw Avastin as a drug to treat metastatic (spread outside of the primary affected organ) breast cancer.